If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

If you are wondering whether Pfizer's current share price offers value or just noise, this article walks through what the ...

Pfizer (PFE) remains in focus for income oriented investors, with recent returns ranging from a 2.1% decline over the past week to a 10.7% total return over the past year. See our latest analysis for ...

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

Pfizer (NYSE: PFE) has been around for 175 years, selling a wide range of drugs in various treatment areas over time. But this pharma giant truly became a household name a few years ago. Pfizer made ...

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals versus peers. The company leads its peer group in EBITDA and revenue growth, ...

Pfizer PFE reported stronger third-quarter results than we anticipated, largely due to significantly higher sales of covid-19 treatment Paxlovid, which also drove management to increase its top- and ...

Activist investor Starboard Value has taken a stake of about $1 billion in Pfizer Inc. and is seeking to spur a turnaround of the struggling pharmaceuticals giant, according to a person familiar with ...

Pfizer’s stock has dropped in the double digits over three years. The company faces declines in sales of its coronavirus products and the loss of exclusivity of other major products. But over the past ...